{"analyses":[{"ciLowerLimit":"-0.93","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.09","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.259","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.107","paramType":"Mean Difference (Final Values)","paramValue":"-0.42","statisticalMethod":"ANCOVA"},{"ciLowerLimit":"-0.78","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.14","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.234","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.174","paramType":"Mean Difference (Final Values)","paramValue":"-0.32","statisticalMethod":"ANCOVA"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.210","value":"0.04"},{"groupId":"OG001","spread":"0.213","value":"-0.38"},{"groupId":"OG002","spread":"0.179","value":"-0.28"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"177"},{"groupId":"OG001","value":"174"},{"groupId":"OG002","value":"272"}],"units":"Participants"}],"description":"The HADS is a 14 item self-assessment scale that determines the levels of anxiety and depression that a patient is experiencing over the past week. The HADS utilizes a 4-point Likert scale (e.g., 0 to 3) for each question and is intended for ages 12 to 65 years. Scores for each domain (anxiety and depression) can range from 0 to 21, with higher scores indicating greater anxiety or depression.\n\nLS mean was calculated using an ANCOVA model which includes geographic region, duration of current episode at baseline (\\<4 years vs. ≥4 years), treatment group and baseline score as fixed factors.","dispersionType":"Standard Error","groups":[{"description":"Participants received two placebo tablets administered orally QD.","id":"OG000","title":"Placebo Phase 3"},{"description":"Participants received one 2 mg Baricitinib tablet administered orally QD, and one placebo tablet administered orally QD to maintain the blind.","id":"OG001","title":"2 mg Baricitinib Phase 3"},{"description":"Participants received one 4 mg Baricitinib tablet administered orally QD, and one placebo tablet administered orally QD to maintain the blind.","id":"OG002","title":"4 mg Baricitinib Phase 3"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"All randomized phase 3 participants with non-missing baseline and at least one post-baseline measurement who had evaluable data for this outcome measure. The method used to handle missing data will be mLOCF which used the most recent nonmissing postbaseline assessment.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 36","title":"Mean Change From Baseline in HADS Depression Score - Phase 3","type":"SECONDARY","unitOfMeasure":"score on a scale"}